Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (151-160 of 220) with videos related to

Pageof 22
Sort By:
HIV Clinical Trials|December 13, 2006
Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activityIvana Maida, Vincent Soriano, Carol Castellares, et al.
The Journal of Infectious Diseases|September 4, 2010
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infectionJudit Morello, Lorena Cuenca, Vincent Soriano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2007
Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patientsBelén Ramos, Marina Núñez, Luz Martín-Carbonero, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapsePablo Labarga, Eugenia Vispo, Pablo Barreiro, et al.
AIDS (London, England)|November 14, 2008
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirinSonia Rodríguez-Nóvoa, Judit Morello, Mar González, et al.
Expert Opinion on Emerging Drugs|March 7, 2008
Emerging drugs for hepatitis CVincent Soriano, Antonio Madejon, Eugenia Vispo, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis CJudit Morello, Vincent Soriano, Pablo Barreiro, et al.
AIDS Research and Human Retroviruses|January 11, 2007
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patientsLuz Martín-Carbonero, Paldma Gil, Teresa García-Benayas, et al.
Gaceta Sanitaria|June 25, 2017
[Hotline for Zika virus: experience of a tropical and travel medicine unit]Marta Díaz-Menéndez, Fernando de la Calle-Prieto, Marta Arsuaga, et al.
The Journal of Infection|November 26, 2013
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapyAntonio Rivero-Juarez, Karin Neukam, Pablo Labarga, et al.
Pageof 22

Showing results (151-160 of 220) with videos related to

Sort By:
Pageof 22
HIV Clinical Trials|December 13, 2006
Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activityIvana Maida, Vincent Soriano, Carol Castellares, et al.
The Journal of Infectious Diseases|September 4, 2010
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infectionJudit Morello, Lorena Cuenca, Vincent Soriano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2007
Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patientsBelén Ramos, Marina Núñez, Luz Martín-Carbonero, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapsePablo Labarga, Eugenia Vispo, Pablo Barreiro, et al.
AIDS (London, England)|November 14, 2008
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirinSonia Rodríguez-Nóvoa, Judit Morello, Mar González, et al.
Expert Opinion on Emerging Drugs|March 7, 2008
Emerging drugs for hepatitis CVincent Soriano, Antonio Madejon, Eugenia Vispo, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis CJudit Morello, Vincent Soriano, Pablo Barreiro, et al.
AIDS Research and Human Retroviruses|January 11, 2007
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patientsLuz Martín-Carbonero, Paldma Gil, Teresa García-Benayas, et al.
Gaceta Sanitaria|June 25, 2017
[Hotline for Zika virus: experience of a tropical and travel medicine unit]Marta Díaz-Menéndez, Fernando de la Calle-Prieto, Marta Arsuaga, et al.
The Journal of Infection|November 26, 2013
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapyAntonio Rivero-Juarez, Karin Neukam, Pablo Labarga, et al.
Pageof 22